Posted by Michael Wonder on 16 Jan 2019
The UK’s new five year pricing agreement
16 January 2019 - Pharma has agreed to capped growth again – in exchange for uptake promises.
The UK has a new five-year Voluntary Pricing and Access Scheme (VPAS) for branded medicines, which came into force on 1 January 2019.
The deal includes a cap of 2% growth on the total medicines bill for each year of the agreement, with any NHS spending over this limit being repaid by the industry.
This is a little higher than the 1.1% rate the medicines bill growth rate has been kept to over the past five years – but much lower than the overall NHS spending growth rate.
